Follow-up Study of Autologous Transplantation of P63+ Lung Progenitor Cells for Treatment of Bronchiectasis

Subjects once received cell treatment Inclusion Criteria: * Subjects diagnosed as bronchiectasis. * Subjects have participated in the clinical trial of autologous transplantation of P63+ LPCs for treatment of bronchiectasis, and actually received LPCs transplantation treatment. * Subjects with stable condition for more than 2 weeks. * Subjects can tolerate bronchoscopy. * Subjects signed informed consent. * Subjects with good compliance. Exclusion Criteria: * Women of childbearing age at the stage of pregnancy or lactation, or those without taking effective contraceptive measures. * Subjects with positive serological tests for hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or syphilis (HBV carriers and patients with stable chronic hepatitis B could be accepted if titers of HBV DNA \< 500 IU/mL or copies \< 1000 copies/mL; patients with curative hepatitis C were eligible if HCV RNA tests were negative). * Subjects with any malignancy. * Subjects with any of the following pulmonary diseases: active tuberculosis, pulmonary embolism, pneumothorax, multiple huge bullae, uncontrolled asthma, acute exacerbation of chronic bronchitis or extremely severe chronic obstructive pulmonary disease (COPD). * Subjects with other serious diseases, such as diabetes, myocardial infarction, unstable angina, cirrhosis, and acute glomerulonephritis. * Subjects with leukopenia (WBC less than 4x10\^9 / L) or agranulocytosis (WBC less than 1.5x10\^9 / L or neutrophils less than 0.5x10\^9 / L) caused by any reason. * Subjects with severe renal impairment, serum creatinine\> 1.5 times of the upper limit of normal. * Subjects with liver disease or liver damage: alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin\> 2 times of the upper limit of normal. * Subjects with a history of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders. * Subjects with severe arrhythmias (such as ventricular tachycardia, frequent superventricular tachycardia, atrial fibrillation, and atrial flutter, etc.) or cardiac degree II or above conduction abnormalities displayed via 12-lead ECG. * Subjects with a history of alcohol or illicit drug abuse. * Subjects accepted by any other clinical trials within 3 months before the enrollment. * Subjects with poor compliance, difficult to complete the study. * Any other conditions that might increase the risk of subjects or interfere with the clinical trial. Subjects providing samples of surgically resected bronchiectasis lesions Inclusion Criteria: * Subjects diagnosed as bronchiectasis. * Subjects have never participated in the clinical trial of autologous transplantation of P63+ LPCs for treatment of bronchiectasis, and never received LPCs transplantation treatment. * Subjects have once received surgery to remove bronchiectasis lesions and lung samples are still kept in the Department of Pathology, Ruijin Hospital till now. * Subjects signed informed consent. Exclusion Criteria: * Women of childbearing age at the stage of pregnancy or lactation, or those without taking effective contraceptive measures. * Subjects with positive serological tests for hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or syphilis (HBV carriers and patients with stable chronic hepatitis B could be accepted if titers of HBV DNA \< 500 IU/mL or copies \< 1000 copies/mL; patients with curative hepatitis C were eligible if HCV RNA tests were negative). * Subjects with any malignancy. * Subjects with any of the following pulmonary diseases: active tuberculosis, pulmonary embolism, pneumothorax, multiple huge bullae, uncontrolled asthma, acute exacerbation of chronic bronchitis or extremely severe COPD. * Subjects with a history of alcohol or illicit drug abuse. * Subjects accepted by any other clinical trials within 3 months before the enrollment.